MedPath

ACCC Initiative Enhances Care Standards for Myeloproliferative Neoplasms Across US Centers

7 months ago3 min read

Key Insights

  • The Association of Cancer Care Centers (ACCC) has completed a three-year quality improvement program focused on implementing best practices for myeloproliferative neoplasms (MPNs) treatment across multiple US healthcare centers.

  • Perlmutter Cancer Center at NYU Langone successfully implemented new protocols, including enhanced symptom tracking, increased clinical trial access, and improved care coordination for MPN patients.

  • The initiative addresses critical challenges in MPN care, including symptom management, financial toxicity affecting 40% of patients, and the need for standardized treatment approaches across regions.

The Association of Cancer Care Centers (ACCC) has concluded a significant three-year quality improvement initiative aimed at advancing care standards for patients with myeloproliferative neoplasms (MPNs), rare blood cancers that present unique diagnostic and treatment challenges.

Understanding MPNs and Current Challenges

MPNs, reclassified as cancers in 2008 by the World Health Organization, encompass three main types: polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). Approximately 20,000 Americans live with these conditions, facing symptoms ranging from fatigue and night sweats to depression and difficulty concentrating.
The disease burden is significant, with many patients experiencing delayed diagnoses due to symptom overlap with other conditions. A 2016 survey revealed that physicians often overestimate patients' ability to recognize MPN-related symptoms, highlighting the need for improved patient education and symptom management strategies.

Quality Improvement Program Implementation

The ACCC program, supported by Incyte, worked with three major institutions through 2024:
  • Perlmutter Cancer Center at NYU Langone Hospital
  • Kent Hospital in Rhode Island
  • Charleston Area Medical Center Vandalia Health

Perlmutter Cancer Center's Success Story

At Perlmutter Cancer Center, which manages approximately 66 MPN patients annually, the quality improvement initiative yielded several significant advances:

Enhanced Patient Care Protocols

  • Implementation of validated MPN Patient Reported Outcomes tools at each visit
  • Increased clinic time, reducing wait times between referral and first visit
  • Establishment of regular multidisciplinary case review meetings

Clinical Trial Integration

The center improved clinical trial access by:
  • Enhancing physician awareness of recruitment criteria
  • Including trial discussions in initial treatment planning
  • Expanding access to community-based research networks

Financial Support and Education

Recognizing that 40% of MPN patients experience financial toxicity, Perlmutter implemented:
  • New screening processes for financial hardship
  • Programs to reduce financial burden
  • Enhanced support systems for affected patients

Symptom Management and Quality of Life

Dr. Andrew Kuykendall from Moffitt Cancer Center, a program participant, emphasized the dual goals of extending life and improving quality of life. The initiative particularly focused on fatigue management, utilizing tools such as the Fatigue Severity Scale and MPN Symptom Assessment Form.

Practice Transformations

Key improvements at participating centers included:
  • Strengthened care coordination among healthcare team members
  • Expanded multidisciplinary education opportunities
  • Enhanced protocols for diagnosis and quality-of-life assessment
  • Improved patient symptom tracking and management systems
The ACCC's initiative represents a significant step forward in standardizing and improving MPN care across the United States, addressing both clinical and quality-of-life aspects of patient care.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.